iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Q4FY23 Preview: Sun Pharmaceutical Industries: Revenue seen at Rs. 106,325 million, PAT at Rs. 18,980 million

22 May 2023 , 09:50 AM

Result date: 26th May, 2023

Recommendation: Buy

Target price: Rs. 1,150

Analysts at IIFL Securities expect Sun Pharmaceutical Industries (Sun Pharma) to post a strong show for the March 2023 quarter. While sequential sales growth could decline owing to Halol import alert; the same is likely to be offset by ramp-up in the Specialty business and Taro. Global Specialty revenue is pegged at $225 million in Q4 versus $222 million in Q3 (ex-milestones).

The company’s EBITDA margin could expand 193 basis points over the year-ago quarter.

Profit After Tax (PAT) growth is estimated at 20% as compared to the year-ago quarter, though it could decline 12% sequentially.


March 2023 estimates

YoY change

QoQ change

Revenue (Rs. mn)




EBITDA (Rs. mn)




EBITDA margin (%)


193 bps

(132) bps

Profit After Tax (Rs. mn)




Source: IIFL Research

Related Tags

  • Sun Pharma
  • Sun Pharma Q4
  • Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries Q4
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.